Conference Call with Gufic BioSciences Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals firm Gufic BioSciences announced Q1FY23 Result : Critical Care Division: Retained leadership position in Anti fungals & Anti bacterials Launch of Dual Chamber Bag initially targeting Anti-infectives. Addressable market size is ~Rs. 3,000 crores Critical Care segment faced headwinds due to reduced hospitalization and excess inventory in the channel. With the launch of Dual Chamber Bags and normalization of hospitalization we see growth coming back in the next few quarters Entered Neurology with unique products, with a special task force, and dedicated training center to broaden the addressable market Ferticare Division: Dydrogesterone: This product is ready for launch. To de-risk, we have vertically integrated with our own API. Market size for this product is ~Rs. 700 crores growing at 60% YoY. We as a Company are planning annual sales of Rs. 20 Crs. in less than 2 years Gufic has invested to develop recombinant alternatives to the urinary source of certain hormones which are critical in the treatment of infertility and thereby ensuring we will be independent of geopolitical as well as currency exchange risks and potential pitfalls in the next 15-18 months Having the widest basket of products along with vertically integrated manufacturing and strong field presence, we intend to be among the top 3 players in the next 3 years in infertility market that is around ~Rs. 4,000 Crs. and growing at 15% Result PDF
Pharmaceuticals company Gufic BioSciences declares Q3FY22 result: The Non-CoVID portfolio of Criticare Group has shown strong growth fueled by Penem Portfolio (Doripenem, Ertapenem, Meropenem, Imipenem & Faropenem) and the Anti Fungal portfolio (Micafungin, Caspofungin & Anidulafungin) Core Infertility Portfolio has nearly doubled. We have seen healthy growth in this portfolio even when compared to the pre-pandemic period due to certain changes in strategies Herbal Products – Launched a new range of Multi-Vitamins which has led to high growth in this segment Spark Division – A new product portfolio will be launched under the Cardiac Diabetic Management in Q2 FY23 Stellar – The division was launched last year, and we are seeing good traction in this segment. We plan to launch 6 to 8 new products in the coming six months Aesthaderm – Stunnox has registered strong growth and continues to see positive trends. This would be one of the pillar brands going ahead Result PDF